Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Helicobacter pylori (H. pylori) enzymes and adhesion factors are a diverse group of bacterial proteins essential for the survival, colonization, and pathogenesis of the bacterium in the human stomach [PMC: 5045270, Wikipedia]. The most prominent enzyme is urease, a nickel-dependent metalloenzyme that neutralizes gastric acid by producing ammonia, thereby creating a neutral microenvironment necessary for bacterial survival [PMC: 11181444, PMC: 11131444, NIH Bookshelf: NBK2447]. Adhesion factors, such as Blood group antigen-binding adhesin (BabA) and Sialic acid-binding adhesin (SabA), are outer membrane proteins that facilitate the specific attachment of H. pylori to the gastric epithelium, preventing its clearance by mucus flow and peristalsis [PMC: 5483515, PMC: 8151465, Frontiers: 2021]. Other factors like γ-glutamyltransferase (gGT) and OipA contribute to metabolic adaptation and the induction of host inflammatory responses [Longevity Today: 2026, PMC: 5045270]. These factors are considered high-value therapeutic targets because their inhibition can prevent initial colonization or eradicate persistent infections, offering an alternative or adjunct to traditional antibiotics which face increasing resistance [J. Med. Microbiol.: 2023, ACS Omega: 2025]. Current pharmacological strategies include the use of urease inhibitors like acetohydroxamic acid and bismuth salts, as well as the development of anti-adhesion agents and probiotics to disrupt bacterial engraftment [Discover Applied Sciences: 2024, ACS Omega: 2025, PubMed: 9600637].
Inhibition of urease activity to prevent gastric acid neutralization [PMC: 11181444, PMC: 11131444]; blockade of adhesin-receptor binding to prevent bacterial attachment to the gastric mucosa [Discover Applied Sciences: 2024, Ace Therapeutics]; competitive exclusion by probiotics [PMC: 11131444]; disruption of bacterial membrane integrity [NIH Bookshelf: NBK2447].
5 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Helicobacter pylori enzymes and adhesion factors.